Post by vintage on May 14, 2018 9:38:05 GMT -8
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
April 2018 CNBC.com
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow." (Story continues at link)
www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html
To me, this is just one more example of the reasons why we should do all we can to look out for our own health, rather than abdicating that responsibility to the “health care” industry. The longer we can be in control of our “self-health” the better.